L. Rhamnosus CNCM I-3690 Composition for Short-Term Stress Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing probiotic strains like L. rhamnosus strains HN001, R0011, LGG & JB-1 have failed to effectively alleviate anxiety and psychological stress in humans, either failing to confirm effects or requiring long-term consumption.

Innovation Solution

Oral administration of L. rhamnosus CNCM I-3690 in a composition comprising at least 10^6 to 10^11 CFU per gram, preferably in dairy or nutraceutical form, for a feasible dosage regimen to reduce anxiety and psychological stress.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing probiotic strains (L. rhamnosus HN001, R0011, LGG, JB-1) are used to alleviate anxiety and psychological stress, then pre-clinical studies show anxiolytic properties, but clinical trials in humans fail to confirm these effects or require extremely long-term consumption

Engineering Contradiction:

Improveeffectiveness of probiotic in reducing anxiety and stressVSAvoidduration of consumption required

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the specific strain parameter from conventional L. rhamnosus strains (HN001, R0011, LGG, JB-1) to a novel strain CNCM I-3690 with different functional characteristics. This parameter change enables the probiotic to achieve anxiety and stress reduction effects in humans within a feasible dosage regimen (1-4 weeks), resolving the contradiction between reliability of effect and time required for consumption.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If probiotic strains are administered to achieve anxiety reduction, then pre-clinical studies show beneficial effects, but clinical translation fails to confirm these effects in humans

Engineering Contradiction:

Improveconfirmation of anxiolytic effects in humansVSAvoidfeasibility of clinical trial implementation

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent modifies the probiotic strain parameters to CNCM I-3690, which has demonstrated superior efficacy in human clinical trials compared to conventional strains. This parameter change enables reliable confirmation of anxiolytic effects in humans within feasible trial durations (1-4 weeks), resolving the contradiction between pre-clinical promise and clinical confirmation.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a short-term clinical trial design (1-4 weeks) to demonstrate efficacy, replacing the need for extremely long-term consumption studies. This approach provides sufficient evidence of anxiolytic effects without requiring prolonged commitment from participants, making clinical translation more feasible and reliable.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If conventional probiotic strains are used, then they are well-studied and safe, but they fail to achieve significant anxiety and stress reduction in human clinical trials

Engineering Contradiction:

Improvesafety and established efficacy of probioticVSAvoidefficacy in reducing psychological stress

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent introduces a novel probiotic strain parameter (CNCM I-3690) that combines safety characteristics with enhanced efficacy. This new strain has been shown to reduce anxiety and stress scores in human clinical trials, resolving the contradiction between established safety and sufficient productivity/efficacy.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP3982988B1Non-therapeutic use of l. rhamnosus CNCM 1-3690 or a composition comprising thereof for the prevention or amelioration of a self-perceived psychological stress in a healthy individual

Publication Date: 2026.04.08 COMPAGNIE GERVAIS DANONE SA

Figure 1~2
Figure 3~4
Figure 5~6

AI summary

The present invention relates to a composition comprising L. rhamnosus CNCM 1-3690 for use in prevention, amelioration or treatment of anxiety and/or psychological stress in an individual.